Literature DB >> 33136750

Validation of the D: A: D Chronic Kidney Disease Risk Score Model Among People Living With HIV in the Asia-Pacific.

Win Min Han1,2, Rimke Bijker1, Ezhilarasi Chandrasekaran3, Sanjay Pujari4, Oon Tek Ng5, Penh Sun Ly6, Man-Po Lee7, Kinh Van Nguyen8, Yu-Jiun Chan9, Cuong Duy Do10, Jun Yong Choi11, Romanee Chaiwarith12, Tuti Parwati Merati13, Sasisopin Kiertiburanakul14, Iskandar Azwa15, Suwimon Khusuwan16, Fujie Zhang17, Yasmin Mohamed Gani18, Junko Tanuma19, Shashikala Sangle20, Rossana Ditangco21, Evy Yunihastuti22, Jeremy Ross23, Anchalee Avihingsanon2,24.   

Abstract

BACKGROUND: We validated the Data collection on Adverse events of anti-HIV Drugs (D:A:D) full-risk and short-risk score models for chronic kidney disease (CKD) in the Asian HIV cohorts. SETTINGS: A validation study among people living with HIV (PLHIV) aged ≥18 years among the cohorts in the Asia-Pacific region.
METHODS: PLHIV with a baseline estimated glomerular filtration rate > 60 mL/min/1.73 m were included for validation of the D:A:D CKD full version and short version without cardiovascular risk factors. Those with <3 estimated glomerular filtration rate measurements from baseline or previous exposure to potentially nephrotoxic antiretrovirals were excluded. Kaplan-Meier methods were used to estimate the probability of CKD development. The area under the receiver operating characteristics was also used to validate the risk score.
RESULTS: We included 5701 participants in full model {median 8.1 [interquartile range (IQR) 4.8-10.9] years follow-up} and 9791 in short model validation [median 4.9 (IQR 2.5-7.3) years follow-up]. The crude incidence rate of CKD was 8.1 [95% confidence interval (CI): 7.3 to 8.9] per 1000 person-years in the full model cohort and 10.5 (95% CI: 9.6 to 11.4) per 1000 person-years in the short model cohort. The progression rates for CKD at 10 years in the full model cohort were 2.7%, 8.9%, and 26.1% for low-risk, medium-risk, and high-risk groups, and 3.5%, 11.7%, and 32.4% in the short model cohort. The area under the receiver operating characteristics for the full-risk and short-risk score was 0.81 (95% CI: 0.79 to 0.83) and 0.83 (95% CI: 0.81 to 0.85), respectively.
CONCLUSION: The D:A:D CKD full-risk and short-risk score performed well in predicting CKD events among Asian PLHIV. These risk prediction models may be useful to assist clinicians in identifying individuals at high risk of developing CKD.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33136750      PMCID: PMC8018533          DOI: 10.1097/QAI.0000000000002464

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.771


  35 in total

1.  Cardiovascular disease-related mortality and factors associated with cardiovascular events in the TREAT Asia HIV Observational Database (TAHOD).

Authors:  R Bijker; A Jiamsakul; E Uy; N Kumarasamy; R Ditango; R Chaiwarith; W W Wong; A Avihingsanon; L P Sun; E Yunihastuti; S Pujari; C D Do; T P Merati; P Kantipong; K V Nguyen; A Kamarulzaman; F Zhang; M P Lee; J Y Choi; J Tanuma; O T Ng; Blh Sim; J Ross; S Kiertiburanakul
Journal:  HIV Med       Date:  2019-01-08       Impact factor: 3.180

2.  Noncommunicable diseases among HIV-infected persons in low-income and middle-income countries: a systematic review and meta-analysis.

Authors:  Pragna Patel; Charles E Rose; Pamela Y Collins; Bernardo Nuche-Berenguer; Vikrant V Sahasrabuddhe; Emmanuel Peprah; Susan Vorkoper; Sonak D Pastakia; Dianne Rausch; Naomi S Levitt
Journal:  AIDS       Date:  2018-07-01       Impact factor: 4.177

3.  Predictors of chronic kidney disease and utility of risk prediction scores in HIV-positive individuals.

Authors:  Emily L Woolnough; Jennifer F Hoy; Allen C Cheng; Rowan G Walker; Anastasia Chrysostomou; Ian Woolley; Freya Langham; Michael A Moso; Achini Weeraratne; Janine M Trevillyan
Journal:  AIDS       Date:  2018-08-24       Impact factor: 4.177

Review 4.  Worldwide access to treatment for end-stage kidney disease: a systematic review.

Authors:  Thaminda Liyanage; Toshiharu Ninomiya; Vivekanand Jha; Bruce Neal; Halle Marie Patrice; Ikechi Okpechi; Ming-hui Zhao; Jicheng Lv; Amit X Garg; John Knight; Anthony Rodgers; Martin Gallagher; Sradha Kotwal; Alan Cass; Vlado Perkovic
Journal:  Lancet       Date:  2015-03-13       Impact factor: 79.321

5.  Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates.

Authors:  Masaru Horio; Enyu Imai; Yoshinari Yasuda; Tsuyoshi Watanabe; Seiichi Matsuo
Journal:  Am J Kidney Dis       Date:  2010-04-22       Impact factor: 8.860

6.  Diminished impact of ethnicity as a risk factor for chronic kidney disease in the current HIV treatment era.

Authors:  Annelot F Schoffelen; Colette Smit; Steven F L van Lelyveld; Liffert Vogt; Martijn P Bauer; Peter Reiss; Andy I M Hoepelman; Roos E Barth
Journal:  J Infect Dis       Date:  2015-01-18       Impact factor: 5.226

7.  The TREAT Asia HIV Observational Database: baseline and retrospective data.

Authors:  Jialun Zhou; N Kumarasamy; Rossana Ditangco; Adeeba Kamarulzaman; Christopher K C Lee; Patrick C K Li; Nicholas I Paton; Praphan Phanuphak; Sanjay Pujari; Asda Vibhagool; Wing-Wai Wong; Fujie Zhang; John Chuah; Kevin R Frost; David A Cooper; Matthew G Law
Journal:  J Acquir Immune Defic Syndr       Date:  2005-02-01       Impact factor: 3.771

8.  Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients.

Authors:  Elżbieta Jabłonowska; Ewa Siwak; Monika Bociąga-Jasik; Jacek Gąsiorowski; Anna Kalinowska; Ewa Firląg Burkacka; Kamila Wójcik-Cichy; Anna Piątek; Iwona Cielniak; Andrzej Horban
Journal:  PLoS One       Date:  2019-01-17       Impact factor: 3.240

9.  Validation of the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) chronic kidney disease risk score in HIV-infected patients in the USA.

Authors:  A M Mills; K L Schulman; J S Fusco; L Brunet; R Hsu; A Beyer; G Prajapati; K Mounzer; G P Fusco
Journal:  HIV Med       Date:  2020-01-27       Impact factor: 3.180

10.  Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study.

Authors:  Mark A Boyd; Amanda Mocroft; Lene Ryom; Antonella d'Arminio Monforte; Caroline Sabin; Wafaa M El-Sadr; Camilla Ingrid Hatleberg; Stephane De Wit; Rainer Weber; Eric Fontas; Andrew Phillips; Fabrice Bonnet; Peter Reiss; Jens Lundgren; Matthew Law
Journal:  PLoS Med       Date:  2017-11-07       Impact factor: 11.069

View more
  1 in total

1.  Incidence of impaired kidney function among people with HIV: a systematic review and meta-analysis.

Authors:  Ruizi Shi; Xiaoxiao Chen; Haijiang Lin; Yingying Ding; Na He
Journal:  BMC Nephrol       Date:  2022-03-17       Impact factor: 2.388

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.